Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer

To evaluate the impact on overall survival at 6, 12 and 18 months of gemcitabine-based doublets compared with gemcitabine alone in patients with advanced and metastatic pancreatic cancer. We conducted a systematic review and meta-analysis of published data on the use of gemcitabine-based doublets co...

Full description

Saved in:
Bibliographic Details
Published in:Drugs & aging 2007-01, Vol.24 (10), p.865-879
Main Authors: BANU, Eugeniu, BANU, Adela, FODOR, Andrei, LANDI, Bruno, ROUGIER, Philippe, CHATELLIER, Gilles, ANDRIEU, Jean-Marie, OUDARD, Stephane
Format: Article
Language:English
Subjects:
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical sciences
Neoplasm Metastasis
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - pathology
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Survival Analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the impact on overall survival at 6, 12 and 18 months of gemcitabine-based doublets compared with gemcitabine alone in patients with advanced and metastatic pancreatic cancer. We conducted a systematic review and meta-analysis of published data on the use of gemcitabine-based doublets compared with gemcitabine alone in chemotherapy-naive patients with advanced and metastatic pancreatic cancer treated in randomised controlled phase II-III trials with overall survival as the principal or secondary endpoint. To this end, a literature search was performed using Cochrane methodology. The relative risks with 95% confidence intervals were estimated based on adjusted number of deaths and patients at risk according to the extent of follow-up and censoring. Twenty-three randomised clinical trials including 5886 patients met the inclusion criteria. In these trials, 2932 patients were randomly assigned to receive gemcitabine-based doublets and 2954 patients to receive gemcitabine alone. Gemcitabine-based doublets were associated with small but significant reductions in the risk of death at 6, 12 and 18 months of 8% (95% CI 3, 13), 4% (95% CI 2, 7) and 3% (95% CI 1, 5), respectively (p
ISSN:1170-229X
1179-1969
DOI:10.2165/00002512-200724100-00006